These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9815525)

  • 1. [Hormone replacement therapy and endometrial cancer].
    Concin H; Sommerlechner M
    Gynakol Geburtshilfliche Rundsch; 1998; 38(2):93-5. PubMed ID: 9815525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen-progestin replacement therapy and endometrial cancer.
    Pike MC; Peters RK; Cozen W; Probst-Hensch NM; Felix JC; Wan PC; Mack TM
    J Natl Cancer Inst; 1997 Aug; 89(15):1110-6. PubMed ID: 9262248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: estrogen-progestin replacement therapy and endometrial cancer.
    McKnight B; Voigt LF; Beresford SA; Weiss NS
    J Natl Cancer Inst; 1998 Jan; 90(2):164-6. PubMed ID: 9450582
    [No Abstract]   [Full Text] [Related]  

  • 4. Are progestins really necessary as part of a combined HRT regimen?
    Sturdee DW
    Climacteric; 2013 Aug; 16 Suppl 1():79-84. PubMed ID: 23651281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations regarding estrogen replacement therapy after treatment of endometrial cancer.
    Creasman WT
    Oncology (Williston Park); 1992 Jul; 6(7):23-6; discussion 26, 28. PubMed ID: 1386238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone replacement therapy and endometrial, ovarian and colorectal cancer.
    Gambacciani M; Monteleone P; Sacco A; Genazzani AR
    Best Pract Res Clin Endocrinol Metab; 2003 Mar; 17(1):139-47. PubMed ID: 12763517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone replacement therapy and the risk of endometrial cancer: A systematic review.
    Sjögren LL; Mørch LS; Løkkegaard E
    Maturitas; 2016 Sep; 91():25-35. PubMed ID: 27451318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy.
    Chubak J; Doherty JA; Cushing-Haugen KL; Voigt LF; Saltzman BS; Hill DA; Beresford SA; Weiss NS
    Cancer Causes Control; 2007 Nov; 18(9):1001-7. PubMed ID: 17653829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy.
    McGonigle KF; Karlan BY; Barbuto DA; Leuchter RS; Lagasse LD; Judd HL
    Gynecol Oncol; 1994 Oct; 55(1):126-32. PubMed ID: 7959253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
    Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
    Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
    Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone replacement therapy and gynecological cancer.
    Gadducci A; Fanucchi A; Cosio S; Genazzani AR
    Anticancer Res; 1997; 17(5B):3793-8. PubMed ID: 9427782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone replacement therapy and endometrial cancer risk: a meta-analysis.
    Grady D; Gebretsadik T; Kerlikowske K; Ernster V; Petitti D
    Obstet Gynecol; 1995 Feb; 85(2):304-13. PubMed ID: 7824251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous combined hormone replacement therapy and risk of endometrial cancer.
    Hill DA; Weiss NS; Beresford SA; Voigt LF; Daling JR; Stanford JL; Self S
    Am J Obstet Gynecol; 2000 Dec; 183(6):1456-61. PubMed ID: 11120510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the problems of the progestogen.
    Sturdee DW; MacLennan AH
    Climacteric; 2006 Aug; 9(4):241-3. PubMed ID: 16857653
    [No Abstract]   [Full Text] [Related]  

  • 16. Hormone replacement therapy and estrogen-dependent cancers.
    Birkhäuser M
    Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():99-114. PubMed ID: 7874193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evidence supporting the rationale for constant oestrogen, intermittent progestogen hormone replacement therapy.
    Rozenberg S
    Eur J Obstet Gynecol Reprod Biol; 2001 Jan; 94(1):86-91. PubMed ID: 11134831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Considerations on hormone replacement therapy].
    Pérez-Caballero MC; León MP; Gimeno LA; Abadía MB
    Med Clin (Barc); 1995 Apr; 104(12):477. PubMed ID: 7739287
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hormone replacement therapy in the climacteric].
    Canto de Cetina TE
    Rev Invest Clin; 1995; 47(1):49-61. PubMed ID: 7777716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.